News

2014 Tribute Pharmaceuticals News Archive

Webcast ImageWebcast
Aralez Pharmaceuticals Inc at RBC Capital Markets 2017 Healthcare Conference  (Replay)
02/22/17 at 1:35 p.m. ET
Aralez Pharmaceuticals Inc at RBC Capital Markets 2017 Healthcare Conference
Wednesday, February 22, 2017 1:35 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Keyword Search
 
2015 | 2014 | 2013
DateTitle 
11/10/14Tribute Pharmaceuticals Reports Double Digit Revenue Growth in Third Quarter 2014
MILTON, ONTARIO--(Marketwired - Nov 10, 2014) - Tribute Pharmaceuticals Canada Inc. (TBUFF) (TSX VENTURE:TRX) ("Tribute" or the "Company"), a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the US, today announced financial results for its third quarter ending September 30, 2014. In this press release, all dollar amounts are expressed in Canadian currency - unless otherwise noted - and results are... 
Printer Friendly Version
11/03/14Tribute Pharmaceuticals Schedules Third Quarter 2014 Financial Results Conference Call
MILTON, ONTARIO -- (Marketwired) -- 11/03/14 --This release corrects and replaces the press release sent on November 3 at 10:26 AM ET for Tribute Pharmaceuticals Canada Inc. In the first paragraph, "second quarter ending September 30, 2014" has been changed to "third quarter ending September 30, 2014". The corrected version follows.Tribute Pharmaceuticals Canada Inc. (OTCQX:TBUFF)(TSX VENTURE:TRX) ("Tribute" or the "Company"), a specialty pharmaceutical company with a primary focus on the acquis... 
Printer Friendly Version
10/30/14Tribute Pharmaceuticals Receives Uracyst(R) Patent in Europe
MILTON, ONTARIO -- (Marketwired) -- 10/30/14 -- Tribute Pharmaceuticals Canada Inc. (OTCQX:TBUFF)(TSX VENTURE:TRX) ("Tribute" or the "Company"), today announced that it has received a patent approval from the European Patent Office ("EPO") for intellectual property central to one of the Company's lead products, Uracyst®/Uropol® (a sterile sodium chondroitin sulfate solution, 2%), for the treatment of interstitial cystitis by instillation into the bladder of a patient. Treatments of other bladder... 
Printer Friendly Version
10/02/14Tribute Pharmaceuticals Announces Acquisition of Canadian Rights to Fiorinal®, Fiorinal® C, Visken® and Viskazide®
- Tribute expects positive EBITDA in Q4 2014 and Fiscal 2015MILTON, ONTARIO -- (Marketwired) -- 10/02/14 -- Tribute Pharmaceuticals Canada Inc. (OTCQX:TBUFF)(TSX VENTURE:TRX) ("Tribute" or the "Company"), is pleased to announce that it has acquired the Canadian rights to Fiorinal®, Fiorinal® C, Visken® and Viskazide® (the "Products") from Novartis AG ("Novartis") for CDN$32 million which was paid in cash on closing. Combined net sales of the Products during the twelve month period ending August ... 
Printer Friendly Version
09/25/14Tribute Pharmaceuticals Receives 4th Uracyst(R) Patent in United States
MILTON, ONTARIO -- (Marketwired) -- 09/25/14 -- Tribute Pharmaceuticals Canada Inc. (OTCQX:TBUFF)(TSX VENTURE:TRX) ("Tribute" or the "Company"), today announced that it has received an additional patent from the U.S. Patent and Trademark Office (USPTO) for intellectual property that is central to one of the Company's lead products, Uracyst® (a sterile sodium chondroitin sulfate solution, 2%, which is used in the treatment of interstitial cystitis / bladder pain syndrome ("IC/BPS")).Tribute's fou... 
Printer Friendly Version
08/11/14Tribute Pharmaceuticals Reports Solid Second Quarter 2014 Results Aug 11,
MILTON, ONTARIO -- (Marketwired) -- 08/11/14 -- Tribute Pharmaceuticals Canada Inc. (OTCQX:TBUFF) (TSX VENTURE:TRX) ("Tribute" or the "Company"), a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and U.S., today announced financial results for its quarter ending June 30, 2014. In this press release, all dollar amounts are expressed in Canadian currency - unless otherwise noted - and results are report... 
Printer Friendly Version
08/06/14Tribute Pharmaceuticals Schedules Second Quarter 2014 Financial Results Conference Call
MILTON, ONTARIO -- (Marketwired) -- 08/06/14 -- Tribute Pharmaceuticals Canada Inc. (OTCQX:TBUFF) (TSX VENTURE:TRX) ("Tribute" or the "Company"), a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S., today announced that it will host a conference call on Monday, August 11, 2014 at 11 AM EDT to review and discuss the Company's results for its second quarter ending June 30, 2014.To join the co... 
Printer Friendly Version
08/05/14Tribute Pharmaceuticals Begins Trading on the OTCQX Marketplace
MILTON, ONTARIO -- (Marketwired) -- 08/05/14 -- Tribute Pharmaceuticals Canada Inc. (OTCQX:TBUFF)(TSX VENTURE:TRX) ("Tribute" or the "Company"), a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S., today announced that its common shares will begin trading today on the OTCQX® marketplace under the symbol "TBUFF". Tribute's common shares will also continue to trade on the TSX Venture Exchange... 
Printer Friendly Version
06/16/14Tribute Pharmaceuticals to Present at the Bloom Burton & Co. Annual Healthcare Conference
LONDON, ONTARIO -- (Marketwired) -- 06/16/14 -- Tribute Pharmaceuticals Canada Inc. ("Tribute" or "the Company") (TSX VENTURE:TRX) (OTCQB:TBUFF), a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S., today announced today that its President and Chief Executive Officer, Rob Harris, will present an update on the Company and its corporate activities, at the Bloom Burton & Co. ("Bloom Burton... 
Printer Friendly Version
05/27/14Tribute Pharmaceuticals Trading on TSX Venture Exchange
MILTON, ONTARIO -- (Marketwired) -- 05/27/14 -- Tribute Pharmaceuticals Canada Inc. (TSX VENTURE:TRX)(OTCQB:TBUFF) ("Tribute" or the "Company"), a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S., announced that effective with the opening of the market today, the Company's common stock is trading under the symbol "TRX" on the TSX Venture Exchange ("TSX-V").Rob Harris, President and CEO for... 
Printer Friendly Version
05/23/14Tribute Pharmaceuticals Receives Approval to List on TSX Venture Exchange
MILTON, ONTARIO -- (Marketwired) -- 05/23/14 -- Tribute Pharmaceuticals Canada Inc. (OTCQB:TBUFF)(OTCBB:TBUFF)(PINKSHEETS:TBUFF) ("Tribute" or the "Company"), a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S., today announced that it has received approval from TSX Venture Exchange ("TSX-V") to add its stock listing, effective with the opening of the market on Tuesday, May 27, 2014. The Co... 
Printer Friendly Version
05/15/14Tribute Pharmaceuticals Reports First Quarter 2014 Results & Schedules First Quarter 2014 Conference Call
MILTON, ONTARIO -- (Marketwired) -- 05/15/14 -- Tribute Pharmaceuticals Canada Inc. (OTCQB:TBUFF)(OTCBB:TBUFF)(PINKSHEETS:TBUFF) ("Tribute" or the "Company"), a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S., today announced financial results for its first quarter ending March 31, 2014. In this press release, all dollar amounts are expressed in Canadian currency - unless otherwise noted ... 
Printer Friendly Version
05/13/14Tribute Pharmaceuticals and Faes Farma Announce Exclusive License Agreement in Canada for Bilastine, a New Treatment Option in the $120 million Allergic Rhinitis and Urticaria Market
MILTON, ONTARIO and MADRID, SPAIN -- (Marketwired) -- 05/13/14 -- Tribute Pharmaceuticals Canada Inc. ("Tribute") (OTCQB:TBUFF)(OTCBB:TBUFF)(PINKSHEETS:TBUFF) (a Canadian specialty pharmaceutical company) and Faes Farma, S.A. ("Faes") (BME:FAE), a Spanish pharmaceutical company, announced today the signing of an exclusive license agreement that grants Tribute the exclusive right to sell Faes's Bilastine product for the treatment of Allergic Rhinitis and Chronic Idiopathic Urticaria (hives) in Ca... 
Printer Friendly Version
05/08/14Tribute Pharmaceuticals Schedules First Quarter 2014 Financial Results Conference Call
MILTON, ONTARIO -- (Marketwired) -- 05/08/14 -- Tribute Pharmaceuticals Canada Inc. (OTCQB:TBUFF)(OTCBB:TBUFF)(PINKSHEETS:TBUFF) ("Tribute" or the "Company"), a Canadian specialty pharmaceutical company engaged in the acquisition, licensing, development and promotion of healthcare products in Canada and United States, today announced that it will host a conference call on Thursday, May 15, 2014 at 11:00 AM EDT (8:00 AM PST) to review and discuss the Company's results for its first quarter ending... 
Printer Friendly Version
03/31/14Tribute Pharmaceuticals Reports Full Year 2013 Results and Lays the Groundwork for Future Growth
MILTON, ONTARIO -- (Marketwired) -- 03/31/14 -- Tribute Pharmaceuticals Canada Inc. (OTCQB:TBUFF)(OTCBB:TBUFF)(PINKSHEETS:TBUFF) ("Tribute" or the "Company"), a Canadian specialty pharmaceutical company engaged in the acquisition, licensing, development and promotion of healthcare products in Canada and the United States, today announced financial results for its fiscal year ending December 31, 2013. In this press release, all dollar amounts are expressed in Canadian currency (unless otherwise n... 
Printer Friendly Version
03/25/14Tribute Pharmaceuticals Schedules 2013 Year End Financial Results Conference Call Mar 25
MILTON, ONTARIO -- (Marketwired) -- 03/25/14 -- Tribute Pharmaceuticals Canada Inc. (OTCQB:TBUFF) ("Tribute" or the "Company"), a Canadian specialty pharmaceutical company engaged in the acquisition, licensing, development and promotion of healthcare products in Canada and US, today announced that it will host a conference call on Monday, March 31, 2014 at 11:00 AM EDT or 8:00 AM PDT to review and discuss the Company's results for its fourth quarter and fiscal year ending December 31, 2013.To jo... 
Printer Friendly Version
03/03/14Tribute Pharmaceuticals Appoints JSB-Partners to Lead Partnership Discussions on Bezalip(R) SR for the US Market
MILTON, ONTARIO -- (Marketwired) -- 03/03/14 -- Tribute Pharmaceuticals Canada Inc. (OTCQB:TBUFF) ("Tribute" or the "Company"), a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada, today announced that it has entered into an agreement with JSB-Partners ("JSB"), a global life sciences advisor, to support Tribute in finding a co-development and commercial partner for the Company's Bezalip® SR (bezafibrate... 
Printer Friendly Version
Data provided by Nasdaq. Minimum 15 minutes delayed.